Bartram, Jack; (2025) Development of a clinically applicable high throughput sequencing of immunoglobulin gene rearrangements in childhood precursor B-cell acute lymphoblastic leukaemia. Doctoral thesis (Ph.D), UCL (University College London).

Preview

Text Bartram_10210984_thesis_Redacted.pdf Download (17MB) | Preview

Abstract

The overall survival of the latest childhood acute lymphoblastic leukaemia (ALL) trial published from the United Kingdom ALL group, UKALL was 92.3%. This excellent outcome was underpinned by accurate risk stratification according to minimal residual disease (MRD) assessment, using allele specific real time quantitative (ASO-RQ) PCR of immunoglobulin gene (IG) and T-cell receptor gene rearrangements, the current gold standard method in Europe. This method has limitations and requires the use of bone marrow (BM). It is only applicable to 92% of patients resulting in 8% of patients getting inferior risk stratification. The quantitative range of ASO-RQ PCR limits the ability to potentially identify patients with an even lower relapse risk who would benefit from protocols that further reduce treatment related mortality. Finally, many groups have demonstrated an unexpectedly complex clonal heterogeneity at diagnosis in patients with ALL and when disease relapse occurs, it often involves clones that were not identified or only viewed as minor clones at diagnosis. To overcome these issues a targeted ultrasensitive and accurate high throughput sequencing (HTS) approach for MRD (HTS-MRD) of immunoglobulin heavy chain (IGH) rearrangements has been developed. Novel bioinformatics pipelines enable interpretation and visualisation of millions of sequencing reads. The technique requires very small amounts of diagnostic DNA and allows quantitative tracking of multiple clones at different time points. As well as giving a more complete picture of clonality at diagnosis, the technique overcomes the secondary/ongoing rearrangements of IG genes during the disease course, which hampers MRD detection. HTS has the potential to increase sensitivity of detection, as sensitivity is limited by the number of cells input to the assay, as opposed to the background amplification in ASO-RQ PCR. This thesis describes the rigorous investigation into multiple sources of potential error during processing in an ultrasensitive assay and mitigations necessary to successfully implement HTS-MRD in clinical practice. The sensitivity is tested to one abnormal cell in one million normal cells threshold. A prospective feasibility study was then performed using peripheral blood instead of BM, concluding HTS-MRD can correctly stratify patients using blood, thereby reducing the need and inherent risks and pain associated with marrow sampling in children. The HTS technique was then applied to cerebrospinal fluid in patients with and without central nervous system (CNS) involvement of leukaemia. The increased sensitivity of detection allowed assessment of the dynamic response of CNS leukaemia throughout treatment and relapse. This, for the first time provided underpinning science to the long-held belief, from clinical observations, that CNS and BM relapses are “competing events” rather than distinct clinical entities. supporting the use of CNS-directed therapy for all children with ALL.

Download activity - last month

Export as XMLCSVJSON

Download activity - last 12 months

Export as JSONCSVXML

Downloads by country - last 12 months

Export as JSONCSVXML

Archive Staff Only

View Item